PL3592732T3 - Wytwarzanie krystalicznego produktu farmaceutycznego - Google Patents

Wytwarzanie krystalicznego produktu farmaceutycznego

Info

Publication number
PL3592732T3
PL3592732T3 PL18709661.5T PL18709661T PL3592732T3 PL 3592732 T3 PL3592732 T3 PL 3592732T3 PL 18709661 T PL18709661 T PL 18709661T PL 3592732 T3 PL3592732 T3 PL 3592732T3
Authority
PL
Poland
Prior art keywords
manufacture
pharmaceutical product
crystalline pharmaceutical
crystalline
product
Prior art date
Application number
PL18709661.5T
Other languages
English (en)
Inventor
Merja Harteva
Anna STAFFANS
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61599196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3592732(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of PL3592732T3 publication Critical patent/PL3592732T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18709661.5T 2017-03-07 2018-02-27 Wytwarzanie krystalicznego produktu farmaceutycznego PL3592732T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20175202 2017-03-07
PCT/FI2018/050143 WO2018162793A1 (en) 2017-03-07 2018-02-27 Manufacture of a crystalline pharmaceutical product

Publications (1)

Publication Number Publication Date
PL3592732T3 true PL3592732T3 (pl) 2025-06-30

Family

ID=61599196

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18709661.5T PL3592732T3 (pl) 2017-03-07 2018-02-27 Wytwarzanie krystalicznego produktu farmaceutycznego

Country Status (23)

Country Link
US (1) US11168058B2 (pl)
EP (2) EP3592732B1 (pl)
JP (1) JP7157071B2 (pl)
KR (3) KR20250065940A (pl)
CN (4) CN121202788A (pl)
AU (1) AU2018229817B2 (pl)
BR (1) BR112019018458A2 (pl)
CA (2) CA3055019C (pl)
CL (2) CL2019002540A1 (pl)
DK (1) DK3592732T3 (pl)
EA (1) EA201992103A1 (pl)
ES (1) ES3027971T3 (pl)
FI (1) FI3592732T3 (pl)
HR (1) HRP20250684T1 (pl)
HU (1) HUE071505T2 (pl)
LT (1) LT3592732T (pl)
MX (1) MX2019010452A (pl)
PL (1) PL3592732T3 (pl)
PT (1) PT3592732T (pl)
RS (1) RS66855B1 (pl)
SI (1) SI3592732T1 (pl)
UA (1) UA126071C2 (pl)
WO (1) WO2018162793A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515040A (ja) 2018-02-27 2021-06-17 サンド・アクチエンゲゼルシヤフト ダロルタミドの結晶形態ｉｉ
SG11202107712SA (en) 2019-01-30 2021-08-30 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
AU2020300043B2 (en) 2019-07-02 2025-03-20 Orion Corporation Pharmaceutical composition of darolutamide
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
WO2022144926A1 (en) * 2020-12-31 2022-07-07 Msn Laboratories Private Limited, R&D Center Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide
EP4486727B1 (en) 2022-02-28 2026-02-25 Química Sintética, S.A. Crystalline form of darolutamide
WO2025229051A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with antiandrogen agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304755A1 (en) * 2005-10-27 2009-12-10 Raghu Rami Reddy Kasu Pharmaceutical formulation of losartan
BRPI0810978B1 (pt) 2007-05-28 2021-05-25 Mitsubishi Shoji Foodtech Co., Ltd Partícula esférica de manitol cristalino
WO2010084515A2 (en) 2009-01-23 2010-07-29 Glenmark Generics Limited A process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof
WO2010103120A1 (en) * 2009-03-12 2010-09-16 Medichem, S.A. New crystals of a benzoylbenzeneacetamide derivative
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
JP5964407B2 (ja) * 2011-04-21 2016-08-03 オリオン コーポレーション アンドロゲン受容体調節カルボキシアミド
CA2833887A1 (en) * 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Drug substances, pharmaceutical compositions and methods for preparing the same
HUE058986T2 (hu) * 2015-01-30 2022-09-28 Orion Corp Egy karboxamid-származék és annak diasztereomerei stabil kristályformában
HUE053958T2 (hu) 2016-08-26 2021-08-30 Bayer Consumer Care Ag Androgén receptor antagonista kristályos formái, elõállítási eljárása és alkalmazása
CN107602471B (zh) 2017-09-22 2021-04-27 成都恒汇化成医药科技有限公司 一种达罗鲁胺的晶型制备方法

Also Published As

Publication number Publication date
CA3055019A1 (en) 2018-09-13
AU2018229817A1 (en) 2019-10-24
UA126071C2 (uk) 2022-08-10
EP3592732B1 (en) 2025-04-09
US20200039940A1 (en) 2020-02-06
JP2020510018A (ja) 2020-04-02
HUE071505T2 (hu) 2025-09-28
CN121021396A (zh) 2025-11-28
HRP20250684T1 (hr) 2025-08-01
KR102676383B1 (ko) 2024-06-20
CA3055019C (en) 2026-02-17
MX2019010452A (es) 2019-10-15
ES3027971T3 (en) 2025-06-17
SI3592732T1 (sl) 2025-07-31
KR20240096691A (ko) 2024-06-26
CN121202788A (zh) 2025-12-26
EP4559527A3 (en) 2025-08-27
CL2019002540A1 (es) 2020-01-31
AU2018229817B2 (en) 2021-09-30
KR20250065940A (ko) 2025-05-13
CA3292509A1 (en) 2026-03-02
EA201992103A1 (ru) 2020-01-24
BR112019018458A2 (pt) 2020-04-14
KR20190126111A (ko) 2019-11-08
RS66855B1 (sr) 2025-06-30
CN121181479A (zh) 2025-12-23
NZ797194A (en) 2025-07-25
WO2018162793A1 (en) 2018-09-13
CL2023002780A1 (es) 2024-01-26
DK3592732T3 (da) 2025-05-19
PT3592732T (pt) 2025-05-09
US11168058B2 (en) 2021-11-09
LT3592732T (lt) 2025-06-10
NZ757848A (en) 2025-05-30
EP4559527A2 (en) 2025-05-28
CN110382467B (zh) 2025-09-26
FI3592732T3 (fi) 2025-05-28
CN110382467A (zh) 2019-10-25
EP3592732A1 (en) 2020-01-15
JP7157071B2 (ja) 2022-10-19

Similar Documents

Publication Publication Date Title
HUE071505T2 (hu) Kristályos gyógyszerkészítmény gyártása
SI3087852T1 (sl) Oralni vrečast proizvod, ki ima pravokotno obliko
IL265239A (en) A process for the production of a solid pharmaceutical preparation
SG11201702299SA (en) Pharmaceutical product
GB201706327D0 (en) A pharmaceutical compound
ZA201805608B (en) Production of crystalline cellulose
EP3154732A4 (en) Method of producing a powder product
ZA201806687B (en) Manufacture of a cereal-based lactic acid-fermented product
IL268344A (en) A system for use in a pharmaceutical product
GB201522771D0 (en) Crystalline form of a phosphate derivative
IL275381A (en) A process for the preparation of Crisborole
SG11201610959PA (en) Novel composition of a confectionery product
IL259394B (en) Reliable prodrugs in pharmaceutical compositions
EP3426646A4 (en) PRODUCTION EQUIPMENT FOR THE PRODUCTION OF A CAPROLACTONE
PT3262905T (pt) Método de calibração de um distribuidor
ZA201800264B (en) Packaging for a medical product
GB201412683D0 (en) Forming a ceramic product
IL268456B (en) A new process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
IL273553A (en) A method for preparing a pharmacy product
GB201610867D0 (en) Crystalline forms of a therapeutic compound and processes for their preparation
PL3043652T3 (pl) Proces sporządzania wyrobów cukierniczych
PT3665183T (pt) Método de preparação de uma composição farmacêutica
IL256429B (en) A production line for the production of medical products, and a production site containing such a production line
ZA201708479B (en) A confectionery product
EP3060196A4 (en) Manufacture of a pharmaceutical product